EDIT vs GS · rev $32.3M vs P/E 20, $324.25B cap
Editas Medicine Inc (EDIT) versus Goldman Sachs Group Inc (GS) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Goldman Sachs Group Inc (GS) is a capital markets company listed on NYSE. It is led by David Solomon.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
GS does not have a complete income-statement cache yet.
EDIT currently screens at market cap $375.2M. GS currently screens at market cap $324.25B and trailing P/E 20.1.
Not investment advice. Open the EDIT and GS stock pages for the full models.
Not investment advice.